MANF is an emerging therapeutic target for metabolic diseases, including diabetes 35, obesity 19, fatty liver 20, alcohol-related diseases, and cardiovascular diseases 36. Here, MANF is linked to obesity due to melanocortin 4 receptor deficiency.